DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award

0
58

Funding Opportunity ID:332710
Opportunity Number:W81XWH-21-PRARP-ADRA
Opportunity Title:DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Grant
Category of Funding Activity:Science and Technology and other Research and Development
Category Explanation:
CFDA Number(s):12.420
Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
Agency Code:DOD-AMRAA
Agency Name:Department of Defense
Dept. of the Army — USAMRAA
Posted Date:Apr 08, 2021
Close Date:Jul 21, 2021
Last Updated Date:Apr 08, 2021
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:$15,000,000
Expected Number of Awards:1
Description:The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD.The FY21 PRARP ADRA encourages applications to consider fluid-based, imaging-based, retinal, or wearable devices as potential diagnostics. Applications must provide a plan that demonstrates access to a suitable cohort and a plan for participant accrual. Suitable cohorts must be relevant to the military risk factor identified as part of the application. Due to nature of the FY21 PRARP ADRA, studies are required to prospectively recruit study participants. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP ADRA applications must be impact-based.
Version:1





Visit the Official Webpage For More Details on DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award

LEAVE A REPLY

Please enter your comment!
Please enter your name here